Dihexa vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Unknown (limited pharmacokinetic data)
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral, SubQ, Topical
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 300-600 mcg
- Frequency
- Daily
- Once daily
- Key Benefits
- Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
- Enhances memory and learning
- May reverse cognitive decline
- Improves neuroplasticity and executive function
- Long-lasting cognitive benefits from short courses
- Potential therapeutic agent for Alzheimer's
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Headache
- Irritability
- Brain fog during washout period
- Unknown long-term effects (insufficient data)
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —